Kringle Pharma Dirección

Dirección controles de criterios 1/4

El CEO de Kringle Pharma es Kiichi Adachi, nombrado en Dec 2016, tiene una permanencia de 7.92 años. posee directamente un 1.12% de las acciones de la empresa, con un valor de ¥66.28M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 5.9 años, respectivamente.

Información clave

Kiichi Adachi

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.9yrs
Participación del CEO	1.1%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Nov 25

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

CEO

Kiichi Adachi (57 yo)

7.9yrs

Permanencia

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kiichi Adachi	President & Director	7.9yrs	sin datos	1.12% ¥ 66.3m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	sin datos	sin datos
Kunio Matsumoto	Chief Scientific Officer	no data	sin datos	sin datos
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	sin datos	sin datos
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	sin datos	sin datos
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	sin datos	sin datos

1.9yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4884 no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kiichi Adachi	President & Director	18.9yrs	sin datos	1.12% ¥ 66.3m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.9yrs	sin datos	sin datos
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	sin datos	sin datos
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	sin datos	sin datos
Kohichiro Yoshino	Independent Outside Director	5.9yrs	sin datos	sin datos
Akihiro Tomoyasu	Part Time Director	7.9yrs	sin datos	sin datos
Kazuto Ninomiya	Audit & Supervisory Board Member	5.9yrs	sin datos	sin datos
Masahiro Motokawa	Audit & Supervisory Board Member	5.9yrs	sin datos	sin datos
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.9yrs	sin datos	sin datos
Masato Fukui	Independent Outside Director	3.9yrs	sin datos	sin datos

5.9yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 4884 se considera experimentada (5.9 años de antigüedad promedio).

Kringle Pharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad